Clinical Studies of New Model Haploidentical Hematopoietic Stem Cell Transplantation

Relapsed and/or Refractory Acute Lymphoblastic Leukemia Clinical Trial

Official title: Clinical Studies of New Model Haploidentical Hematopoietic Stem Cell Transplantation

Status Recruiting

Clinical Trial Summary

Building a new haploid transplanted model with high-dose CTX、CD19-CART,donor CD34+ hematopoietic stem cell and Tregs,to prevent graft-versus-host disease(GVHD),reduce the infection,promote the rate of immune reconstruction，seperate graft versus leukemia（GVL）and GVHD，then to reduce the relapse rate after hematopoietic stem cell transplantation（HSCT）for relapsed and/or refractory B cell acute lymphoblastic leukemia（r/r-B-ALL）.

Clinical Trial Description

compare the new haplo-HSCT model with the traditional haplo-HSCT in DFS、OS、RFS、CR and the degree of GVHD.etc.for the r/r B-ALL patients. ;

Related Conditions & MeSH terms

• CD19-chimeric Antigen Receptor T Cells
• Precursor Cell Lymphoblastic Leukemia-Lymphoma
• Relapsed and/or Refractory Acute Lymphoblastic Leukemia
• the Haploidentical Hematopoietic Stem Cell Transplantation

• NCT number: NCT03423706
• Study type: Interventional
• Source: First Affiliated Hospital of Harbin Medical University
• Contact: min li li, master
• Phone: 13796615495
• Email: llilimin@163.com
• Status: Recruiting
• Phase: N/A
• Start date: May 7, 2018
• Completion date: December 2021